Source-grounded facts extracted from Scinai Immunotherapeutics Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Scinai Immunotherapeutics Ltd. entered into License Agreement with Max-Planck-Innovation GmbH and the University Medical Center Gottingen (effective 2023-06-04).
“On June 4, 2023, BiondVax Pharmaceuticals Ltd. (the “Company” or “BiondVax”) entered into a License Agreement (the “License Agreement”) with the Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany(“MI”) and the University Medical Center Gottingen (“UMG”) to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) (the “Target”) as treatments for all potential indications.”
George H. Lowell resigned as Director at Scinai Immunotherapeutics Ltd..
“On May 10, 2023, Mr. George H. Lowell submitted to the board of directors (the “Board”) of BiondVax Pharmaceuticals Ltd. (the “Company”) his resignation from his position as a member of the Board, effective May 12, 2023.”
Listing & Compliance Notices
Scinai Immunotherapeutics Ltd. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 1, 2023, BiondVax Pharmaceuticals Ltd. (the “ Company ”) received a deficiency letter from the staff of the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “ Stockholders’ Equity Requirement ”). The Company’s Annual Report on Form 10-K for the year ended”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.